CytoDyn Inc. (CYDY) Making Waves in the HIV Treatment Space
To date, the standard of care for men and women with the human immunodeficiency virus (HIV) has been a mix of medications, often pills, from different antiretroviral classes that hinder different steps of the HIV lifecycle. Although generally effective, the drug regimens that currently dominate the HIV treatment space also have limitations. They require daily dosing. They are linked with side-effects. They are vulnerable to drug resistance. And, in some patients, they are simply not effective. As a result, there are long-term HIV survivors who are now dealing with issues of drug resistance and need new treatment options.
There is general agreement within the medical community that HIV treatments will soon be dispensed through subcutaneous or intra-muscular injections. Biotech companies at the forefront of this space, including ViiV Healthcare (a subsidiary of GlaxoSmithKline), Janssen Pharmaceuticals, and CytoDyn Inc. (OTCQB: CYDY), are now developing this category of drugs and have progressed to the late stages of clinical development.
CytoDyn, with its focus on improving the standard of living for HIV patients, has plans for new breakthrough therapies that serve the unmet needs of a growing number of treatment-experienced HIV patients with virologic failure.
One of the monoclonal antibodies that CytoDyn has under development is its lead drug candidate, PRO 140, a therapeutic anti-viral agent in Phase III clinical trial for the treatment of persons already infected with HIV. With several potential benefits, including less frequent dosing and minimal side effects, PRO 140 belongs to a new class of HIV/AIDS therapeutics that protects healthy cells from viral infection. Last month, CytoDyn took an important step to further distinguish PRO 140 from currently-used HIV treatments. It filed a request with the U.S. Food and Drug Administration asking the federal agency to assign PRO 140 the Breakthrough Therapy Designation.
To learn more about this biotech company’s breakthrough therapies, visit www.CytoDyn.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
To date, the standard of care for men and women with the human immunodeficiency virus (HIV) has been a mix of medications, often pills, from different antiretroviral classes that hinder different steps of the HIV lifecycle. Although generally effective, the drug regimens that currently dominate the HIV treatment space also have limitations. They require daily dosing. They are linked with side-effects. They are vulnerable to drug resistance. And, in some patients, they are simply not effective. As a result, there are long-term HIV survivors who are now dealing with issues of drug resistance and need new treatment options.
There is general agreement within the medical community that HIV treatments will soon be dispensed through subcutaneous or intra-muscular injections. Biotech companies at the forefront of this space, including ViiV Healthcare (a subsidiary of GlaxoSmithKline), Janssen Pharmaceuticals, and CytoDyn Inc. (OTCQB: CYDY), are now developing this category of drugs and have progressed to the late stages of clinical development.
CytoDyn, with its focus on improving the standard of living for HIV patients, has plans for new breakthrough therapies that serve the unmet needs of a growing number of treatment-experienced HIV patients with virologic failure.
One of the monoclonal antibodies that CytoDyn has under development is its lead drug candidate, PRO 140, a therapeutic anti-viral agent in Phase III clinical trial for the treatment of persons already infected with HIV. With several potential benefits, including less frequent dosing and minimal side effects, PRO 140 belongs to a new class of HIV/AIDS therapeutics that protects healthy cells from viral infection. Last month, CytoDyn took an important step to further distinguish PRO 140 from currently-used HIV treatments. It filed a request with the U.S. Food and Drug Administration asking the federal agency to assign PRO 140 the Breakthrough Therapy Designation.
To learn more about this biotech company’s breakthrough therapies, visit www.CytoDyn.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
